-
Brown KS, Keogh MJ, Tagiuri N, Grainge MJ, Presanis JS, RyderSD , Irving WL, Ball JK, Sim RB, Hickling TP, 2007: Severefibrosis in hepatitis C virus-infected patients is associated with increased activity of the mannan-binding lectin (MBL)/MBL-associatedserine protease 1 (MASP-1) complex[J]. Clin Exp Immunol, 147, 90-98.
-
Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ, 1994: Classification of chronic hepatitis: diagnosis, grading andstaging[J]. Hepatology, 19, 1513-1520. doi: 10.1002/(ISSN)1527-3350
-
Dunkelberger JR, Song WC, 2010: Complement and its role in innate and adaptive immune responses[J]. Cell Res, 20, 34-50. doi: 10.1038/cr.2009.139
-
Eisen DP, Minchinton RM, 2003: Impact of mannose-binding lectin on susceptibility to infectious diseases[J]. Clin Infect Dis, 37, 1496-1505. doi: 10.1086/379324
-
El-Serag HB, 2012: Epidemiology of viral hepatitis and hepatocellular carcinoma[J]. Gastroenterology, 142, 1264-1273. doi: 10.1053/j.gastro.2011.12.061
-
Endo Y, Sato Y, Matsushita M, Fujita T, 1996: Cloning and characterization of the human lectin P35 gene and its related gene[J]. Genomics, 36, 515-521. doi: 10.1006/geno.1996.0497
-
Esmat S, Omran D, Sleem GA, Rashed L, 2012: Serum mannan-binding lectin in egyptian patients with chronic hepatitisC: its relation to disease progression and response to treatment[J]. Hepat Mon, 12, 259-264. doi: 10.5812/hepatmon
-
European Association for the Study of the Liver, 2012: EASL clinical practice guidelines: Management of chronic hepatitis B virus infection[J]. J Hepatol, 57, 167-185. doi: 10.1016/j.jhep.2012.02.010
-
Hoang TV, Toan NL, Song le H, Ouf EA, Bock CT, Kremsner PG, Kun JF, Velavan TP, 2011: ficolin-2 levels and FCN2 haplotypes influence hepatitis B infection outcome in Vietnamese patients[J]. PLoS One, 6, e28113-. doi: 10.1371/journal.pone.0028113
-
Holmskov U, Thiel S, Jensenius JC. 2003. Collections and ficolins: humoral lectins of the innate immune defense. Annu RevImmunol, 21.
-
Honore C, Rorvig S, Hummelshoj T, Skjoedt MO, Borregaard N, Garred P, 2010: Tethering of ficolin-1 to cell surfaces through recognition of sialic acid by the fibrinogen-like domain[J]. J Leukoc Biol, 88, 145-158. doi: 10.1189/jlb.1209802
-
Hu YL, Luo FL, Fu JL, Chen TL, Wu SM, Zhou YD, Zhang XL, 2013: Early increased ficolin-2 concentrations are associated with severity of liver inflammation and efficacy of anti-viral therapy in chronic hepatitis C patients[J]. Scand J Immunol, 77, 144-150. doi: 10.1111/sji.12014
-
Hummelshoj T, Munthe-Fog L, Madsen HO, Fujita T, Matsushita M, Garred P, 2005: Polymorphisms in the FCN2 gene determine serum variation and function of ficolin-2[J]. Hum Mol Genet, 14, 1651-1658. doi: 10.1093/hmg/ddi173
-
Hummelshoj T, Munthe-Fog L, Madsen HO, Garred P, 2008: Functional SNPs in the human ficolin (FCN) genes reveal distinct geographical patterns[J]. Mol Immunol, 45, 2508-2520. doi: 10.1016/j.molimm.2008.01.003
-
Jeong WI, Gao B, 2008: Innate immunity and alcoholic liver fibrosis[J]. J Gastroenterol Hepatol, 23, S112-S118.
-
Kilpatrick DC, Delahooke TE, Koch C, Turner ML, Hayes PC, 2003: Mannan-binding lectin and hepatitis C infection[J]. Scand J Gastroenterol, 132, 92-95.
-
Li J, Wu W, Peng G, Chen F, Bai M, Zheng M, Chen Z, 2010: HBcAg induces interleukin-10 production, inhibiting HBcAg-specific Th17 responses in chronic hepatitis B patients[J]. Immunol Cell Biol, 88, 834-841. doi: 10.1038/icb.2010.63
-
Liu J, Ali MA, Shi Y, Zhao Y, Luo F, Yu J, Xiang T, Tang J, Li D, Hu Q, Ho W, Zhang X, 2009: Specifically binding of L-ficolin to N-glycans of HCV envelope glycoproteins E1 and E2 leads to complement activation[J]. Cell Mol Immunol, 6, 235-244. doi: 10.1038/cmi.2009.32
-
Liu Y, Endo Y, Iwaki D, Nakata M, Matsushita M, Wada I, Inoue K, Munakata M, Fujita T, 2005: Human M-ficolin is a secretory protein that activates the lectin complement pathway[J]. J Immunol, , 3150-3156.
-
Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association, Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Association CM, 2006: Diagnostic and treatment guidelines for liver failure[J]. Zhonghua Gan Zang Bing Za Zhi, 14, 643-646.
-
Mannan R, Misra V, Misra SP, Singh PA, Dwivedi M, 2014: A comparative evaluation of scoring systems for assessing necro-inflammatory activity and fibrosis in liver biopsies of patients with chronic viral hepatitis[J]. J Clin Diagn Res, 8, FC08-12.
-
Matsushita M, Endo Y, Taira S, Sato Y, Fujita T, Ichikawa N, Nakata M, Mizuochi T, 1996: A novel human serum lectin with collagen-and fibrinogen-like domains that functions as an opsonin[J]. J Biol Chem, 271, 2448-2454. doi: 10.1074/jbc.271.5.2448
-
Pan Q, Chen H, Wang F, Jeza VT, Hou W, Zhao Y, Xiang T, Zhu Y, Endo Y, Fujita T, 2012: L-Ficolin Binds to the Glycoproteins Hemagglutinin and Neuraminidase and Inhibits Influenza A Virus Infection Both in vitro and in vivo[J]. J Innate Immun, 4, 312-324. doi: 10.1159/000335670
-
Poynard T, Yuen MF, Ratziu V, Lai CL, 2003: Viral hepatitis C[J]. Lancet, 362, 2095-2100. doi: 10.1016/S0140-6736(03)15109-4
-
Ren Y, Ding Q, Zhang X, 2014: Ficolins and infectious diseases[J]. Virol Sin, 29, 25-32. doi: 10.1007/s12250-014-3421-2
-
Song WC, Sarrias MR, Lambris JD, 2000: Complement and innate immunity[J]. Immunopharmacology, 49, 187-198. doi: 10.1016/S0162-3109(00)80303-3
-
Sugimoto R, Yae Y, Akaiwa M, Kitajima S, Shibata Y, Sato H, Hirata J, Okochi K, Izuhara K, Hamasaki N, 1998: Cloning and characterization of the Hakata antigen, a member of the ficolin/opsonin p35 lectin family[J]. J Biol Chem, 273, 20721-20727. doi: 10.1074/jbc.273.33.20721
-
Walport MJ, 2001: Complement[J]. First of two parts. N Engl J Med, 344, 1058-1066. doi: 10.1056/NEJM200104053441406
-
Wang H, Xue L, Yan R, Zhou Y, Wang MS, Cheng MJ, Hai-Jun H, 2013: Comparison of histologic characteristics of Chinese chronic hepatitis B patients with persistently normal or mildly elevated ALT[J]. PLoS One, 8, e80585-. doi: 10.1371/journal.pone.0080585
-
Zhao Y, Ren Y, Zhang X, Zhao P, Tao W, Zhong J, Li Q, Zhang XL, 2014: ficolin-2 inhibits hepatitis C virus infection, whereas apolipoprotein E3 mediates viral immune escape[J]. J Immunol, 193, 783-796. doi: 10.4049/jimmunol.1302563